Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock "overdone.

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

an upgrade came to Novo Nordisk from UBS from Neutral to a Buy rating. The recent sell-off in Novo Nordisk's stock for its Carigsema was seen as overdone, thus unveils an attractive entry point.

Equities research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for Novo Nordisk ...

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” to continue to benefit from the high demand for ...

On Monday, Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.62 which represents a decrease of $-1.64 or -1.90% from the prior close of $86.26. The stock opened at $84.42 and touched a ...

Novo Nordisk saw its stock price increase in both Denmark and the United States today following an upgrade from UBS. UBS analysts now recommend “Buy” on Novo Nordisk’s stock, although they ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...